This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaSeek Implements Allegro CTMS For Clinical Research Site Management

MADISON, Wis., April 4, 2013 /PRNewswire/ -- Forte Research Systems, Inc., developer of specialized clinical research management software, announced that PharmaSeek, an Investigative Site Network, has implemented its Allegro Clinical Trial Management System (CTMS) to support their rapidly growing operations and help manage multiple trials running simultaneously. The investigative site network switched to the CTMS when they outgrew their existing system. 


"We evaluated several CTMS systems and Forte allowed for an easy-to-use and highly-customizable platform. Forte's willingness to rely on feedback to continually make system updates and enhancements was critical in our decision making process," said Lindsay McCarthy, Director of Operations at PharmaSeek.

When beginning development of the multi-site edition of the Allegro CTMS system in 2011, Forte established collaboration with PharmaSeek so the network could provide insight and guidance with regard to the unique needs of networks.  

The multi-site edition of Allegro CTMS was released in January 2012 with features such as a site database, project management tools, subject visit scheduling, and financial management functionality. After migrating all their data into the Allegro CTMS system, PharmaSeek has found the site selection and project management tools particularly useful.

"In Allegro CTMS, site selection is more streamlined than ever, allowing our team to quickly identify potential sites for new study opportunities," says McCarthy. "We are now able to quickly and easily retrieve qualified sites based on site-specific search criteria, such as therapeutic areas, phases a site can participate in, and equipment available at each site." 

Additionally, contact information and documents such as investigator credentials are easily accessible, eliminating the need for repeated collection for each study protocol. The system also tracks expiration dates of these documents, so PharmaSeek can contact the site, if needed, to ensure they have the most current documents on file.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs